10,000 Shares in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Acquired by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS bought a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $329,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AGIO. State Street Corp grew its position in shares of Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock valued at $103,586,000 after acquiring an additional 216,484 shares during the period. Geode Capital Management LLC grew its holdings in Agios Pharmaceuticals by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after purchasing an additional 6,101 shares during the period. Frazier Life Sciences Management L.P. grew its holdings in Agios Pharmaceuticals by 19.7% during the third quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company’s stock valued at $46,392,000 after purchasing an additional 172,180 shares during the period. Fisher Asset Management LLC raised its stake in shares of Agios Pharmaceuticals by 12.3% in the fourth quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company’s stock worth $31,567,000 after buying an additional 105,333 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Agios Pharmaceuticals by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 472,547 shares of the biopharmaceutical company’s stock worth $15,528,000 after buying an additional 6,927 shares during the period.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now directly owns 18,906 shares of the company’s stock, valued at $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.93% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

AGIO has been the subject of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $58.00 target price on the stock. StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Royal Bank of Canada raised their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Finally, Scotiabank upped their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $56.57.

Agios Pharmaceuticals Trading Down 7.0 %

NASDAQ:AGIO opened at $25.76 on Friday. The business’s 50-day moving average is $32.55 and its 200 day moving average is $40.23. Agios Pharmaceuticals, Inc. has a 12 month low of $25.26 and a 12 month high of $62.58. The company has a market capitalization of $1.48 billion, a P/E ratio of 2.27 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.